The abstract is read at the publisher; the summary is JClub's.
HLA-A, HLA-B, and HLA-C class I and DRB1–DQB1 class II polymorphisms are linked to pediatric neuroblastoma susceptibility and outcomes, with strongest evidence for OS and PFS.
- Why it matters: Pediatric neuroblastoma arises in an immature immune system, and inherited immunogenetic differences may shape immune recognition, yet their roles are less defined than in blood cancers.
- What they did: The review structuredly synthesized case-control and cohort studies of pediatric neuroblastoma, organizing results by population, sample size, HLA locus, and association strength, including tumor HLA expression and antigen-presentation defects.
- The result: Evidence suggests class I variants influence cytotoxic T-cell and NK function, while DRB1–DQB1 (including DQB1 * 05:02 and DRB1*16:01) is linked to CD4 T-cell responses; some associations are subtype-specific (e.g., MYCN-amplified), and specific class I variants correlate with OS/PFS, including in anti-GD2 immunotherapy and post–hematopoietic stem cell transplantation settings.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.